Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A germ cell tumor arising from the testis. Representative examples include teratoma, seminoma, embryonal carcinoma, and yolk sac tumor.
Features include: Teratoma, Choriocarcinoma, Elevated circulating alpha-fetoprotein concentration, and Embryonal neoplasm and 1 more.
Organ System
Phenotype Count |
|---|
Example Features |
|---|
Lab test results | 1 | Elevated circulating alpha-fetoprotein concentration |
KIT encodes KIT proto-oncogene, receptor tyrosine kinase (976 aa). Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. Highest expression in Esophagus Muscularis (44.5 TPM) and Ovary (36.4 TPM).
Testicular germ cell tumor is associated with mutations in the KIT gene on chromosome 4.
The KIT protein participates in KIT V559_V560del, KIT K550_K558del, and KIT P551_V555del pathways.
KIT is classified as a druggable target (Clinically Actionable, Drug Resistance, Druggable Genome, External Side Of Plasma Membrane, Kinase, Transcription Factor, and Tyrosine Kinase categories) with score 2.1.
STK11 function has not been fully characterized.
Testicular germ cell tumor is associated with mutations in the STK11 gene on chromosome 19.
Genetic testing for KIT, STK11 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for testicular germ cell tumor has been reported in the published literature.
10 clinical trials registered, 5 recruiting. Interventions under study include other interventions, procedural interventions, drug therapy, and biologic therapy. Pipeline includes 2 PHASE1, 3 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06276491](https://clinicaltrials.gov/study/NCT06276491) | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | PHASE1 | Xencor, Inc. | RECRUITING |
[NCT07453082](https://clinicaltrials.gov/study/NCT07453082) | A Prospective Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumors | — | Fondazione del Piemonte per l'Oncologia | RECRUITING |
[NCT06060873](https://clinicaltrials.gov/study/NCT06060873) | MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial | — | University of Southern California | RECRUITING |
[NCT05670938](https://clinicaltrials.gov/study/NCT05670938) | Follow-up After Surgery for Testicular Cancer | — | Erasmus Medical Center | RECRUITING |
[NCT07777887](https://clinicaltrials.gov/study/NCT07777887) | Sentinel Node Identification Using Gamma and Near-Infrared Imaging in TesticulAr MaLignancies | — | N.N. Petrov National Medical Research Center of Oncology | RECRUITING |
203 publications have been identified in PubMed for testicular germ cell tumor. Research spans Basic Science / Preclinical (28%), Review / Meta-Analysis (19%), and Epidemiology / Natural History (19%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 50 | 28% |
Research summaries | 35 | 19% |
Disease patterns and progression | 34 | 19% |
Testing and diagnosis research | 20 | 11% |
Patient case studies | 17 | 9% |
Clinical study results | 14 |
Bremmer F (2026). [PMID: 41384704](https://pubmed.ncbi.nlm.nih.gov/41384704/). *Histopathology*. [Review / Meta-Analysis]
Tekinaslan H (2026). [PMID: 40944935](https://pubmed.ncbi.nlm.nih.gov/40944935/). *Urol Int*. [Diagnostic / Biomarker]
Conduit C (2026). [PMID: 41835342](https://pubmed.ncbi.nlm.nih.gov/41835342/). *Ther Adv Med Oncol*. [Epidemiology / Natural History]
Liu G (2026). [PMID: 42131333](https://pubmed.ncbi.nlm.nih.gov/42131333/). *Front Immunol*. [Diagnostic / Biomarker]
Choi S (2026). [PMID: 41674621](https://pubmed.ncbi.nlm.nih.gov/41674621/). *medRxiv*. [Basic Science / Preclinical]
Chen S (2026). [PMID: 41593694](https://pubmed.ncbi.nlm.nih.gov/41593694/). *Diagnostic pathology*. [Diagnostic / Biomarker]
Islam R (2026). [PMID: 41773555](https://pubmed.ncbi.nlm.nih.gov/41773555/). *Andrology*. [Review / Meta-Analysis]
Oliveira-Lopes B (2026). [PMID: 41128509](https://pubmed.ncbi.nlm.nih.gov/41128509/). *Current opinion in urology*. [Review / Meta-Analysis]
Alfano M (2026). [PMID: 40658795](https://pubmed.ncbi.nlm.nih.gov/40658795/). *The Journal of clinical endocrinology and metabolism*. [Gene Therapy / Novel Therapeutics]
Bowling GC (2026). [PMID: 41687980](https://pubmed.ncbi.nlm.nih.gov/41687980/). *Gene*. [Case Report / Case Series]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 6:47 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
New treatment approaches | 10 | 6% |
AI-curated news mentioning testicular germ cell tumor
Updated Sep 15, 2026
A recent case study highlights a rare testicular tumor occurring alongside synchronous malignancy, contributing to the understanding of complex tumor presentations. This case adds to the limited literature on such rare occurrences.
A new study identifies risk factors and causes of early death in germ cell tumors, providing critical insights for improving patient outcomes. This research highlights the need for targeted interventions in this rare cancer population.
A recent publication reviews treatment options for platinum-refractory male germ cell cancers, highlighting current standards and potential future directions. This research aims to improve outcomes for patients who do not respond to standard platinum-based therapies.